Botwood Nicholas A.J. sold $1.2M of SNDX
Botwood Nicholas A.J. (Head of R&D, CMO) sold 65,515 shares of Syndax Pharmaceuticals Inc (SNDX) at an average of $18.07 ($18.00–$18.14, $1.18M total) across 2 trades over 2026-06-11 to 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the officer’s open-market sale size and timing, along with confirmation that it was executed under a pre-arranged Rule 10b5-1 plan.
Market read
Traders may monitor for sentiment drift, but the 10b5-1 structure makes this more of a routine flow than a new fundamental catalyst.
What to watch
Check whether there were concurrent insider buys/sales by other officers/directors and whether the company has upcoming clinical/regulatory milestones that could dominate price action.
Background
The article is an SEC Form 4 insider transaction disclosure for Syndax Pharmaceuticals (SNDX).
Ticker impact
Syndax Pharmaceuticals insider Form 4 shows Head of R&D/CMO Nicholas Botwood sold 65,515 shares for ~$1.18M via an open-market sale under a 10b5-1 plan.
Likely minimal immediate price impact; any effect would be sentiment-driven and short-lived.
The filing is a primary-source insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No direct sector read-across; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations, so traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerSyndax Pharmaceuticals Inc
Biopharma company whose insider transaction is disclosed on SEC Form 4.
- insiderNicholas A.J. Botwood
Head of R&D and CMO who sold 65,515 shares for ~$1.18M under a 10b5-1 plan.
